|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/454 | |
| A61K 31/282 | |||
| A61K 31/357 | |||
| A61K 31/366 | |||
| A61K 31/4035 | |||
| A61K 31/541 | |||
| A61K 31/7068 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Number of the document | 2521543 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11700288.1 |
| Date of filing the European patent application | 2011-01-05 | |
| (97) | Date of publication of the European application | 2012-11-14 |
| (45) | Date of publication and mention of the grant of the patent | 2016-04-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/020160 |
| Date | 2011-01-05 |
| (87) | Number | WO 2011/084968 |
| Date | 2011-07-14 |
| (30) | Number | Date | Country code |
| 371347 P | 2010-08-06 | US | |
| 292307 P | 2010-01-05 | US |
| (72) |
DALGLEISH, Angus, GB
GRAVETT, Andrew, GB
LIU, Wai, GB
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (54) | A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ DERIVATIVE FOR TREATING CANCER |
| A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ DERIVATIVE FOR TREATING CANCER |